# US 2020/0392156 A1 · Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392156 A1
- Document ID: US20200392156A1
- Status: Published application
- Kind: A1
- Application number: 16/904,073
- Filed: 2020-06-17
- Published: 2020-12-17
- Earliest claimed: 2019-06-17
- Assignees: Petra Pharma Corporation
- Applicants: Petra Pharma Corporation
- Inventors: Edward A. KESICKI
- Web page: https://patentgrep.com/patent/US20200392156A1

## CPC

- C07D 491/06: Peri-condensed systems
- C07D 498/14: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- C07D 471/12: in which the condensed system contains three hetero rings
- C07D 471/14: Ortho-condensed systems
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof,
wherein:
A is aryl;
B is heteroaryl, substituted with one or more R8, provided that when B is heteroaryl, B is not bonded through its heteroatom;
X1 is C(R5);
X2 is C(R5) or N;
W is C(R6);
R1 is —N(R2)C(O)R3, —C(O)N(R2)(R3), —P(O)(R2)(R3), or heteroaryl, wherein the heteroaryl is optionally substituted with one or more R7;
R2 is independently, at each occurrence, C1-6 alkyl;
R3 is independently, at each occurrence, C1-6 alkyl or C3-8 cycloalkyl; or
R2 and R3 when taken together with the atom to which they are each attached form a heterocycle optionally substituted with one or more R4;
R4 is independently —H or C1-6 alkyl;
R5 is independently —H;
R6 is —H, —N(R26)(R27), C1-6 alkoxy, heterocyclyl, C1-6 alkenyl, C1-6 haloalkyl, or C1-6 alkyl, wherein the alkyl, alkenyl, alkoxy, or heterocyclyl, is optionally substituted with one or more —OH, —CN, C1-6 alkyl, or heterocyclyl;
R7 is C1-6 alkyl;
R8 is heterocyclyl, —N(R9)(R10), or —OR10, wherein the heterocyclyl is optionally substituted with one or more R15; or
two R8 groups, together with the atoms to which they are attached, form a heterocyclyl, optionally substituted with one or more R15;
each R9 or R10 is independently, at each occurrence, C1-6 alkyl optionally substituted with one or more R11;
R11 is —OH, heterocyclyl, —C(O)R17, or —C(O)N(R23)(R23), wherein the heterocyclyl is optionally substituted with one or more R17;
R15 is —N(C1-6 alkyl)2, C1-6 alkyl, —C(O)N(R21)(R23), —(CH2)o—C(O)R23, or —C(O)OR23, wherein the alkyl, is optionally substituted with one or more R23; or
two R15 groups, together with the atoms to which they are attached, form a heterocyclyl optionally substituted with one or more R20;
R17 is halogen or C1-6 alkyl;
R20 is independently oxo or C1-6 alkyl, wherein the C1-6 alkyl is substituted with heterocyclyl;
R21 is —H or C1-6 alkyl;
each R23 is independently C1-6 alkyl, optionally substituted with one or more —N(C1-6 alkyl)2; or
two R23 together form a heterocyclyl, wherein the heterocyclyl is optionally substituted by C1-6 alkyl;
R26 is —H or C1-6 alkyl;
R27 is C1-6 alkyl, heterocyclyl, or cycloalkyl, wherein the alkyl, heterocyclyl, or cycloalkyl is optionally substituted with one or more halogen, —CN, —C(O)OH, —OH, or —NH2; and
each o is independently 0-4,
provided that R8 is not methoxy.

### Claim 2 (depends on 1)

The compound of claim 1 having the Formula (Ia):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 3 (depends on 1)

The compound of claim 1 having the Formula (Ib):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 4 (depends on 1)

The compound of claim 1 having the Formula (Ic):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 5 (depends on 1)

The compound of claim 1 having the Formula (Id):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 6 (depends on 1)

The compound of claim 1 having the Formula (Ie):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 7 (depends on 1)

The compound of claim 1 having the Formula (If):
wherein X2 is C(R5) or N and W is C(R6).

### Claim 8 (depends on 1)

The compound of claim 1 selected from the group consisting of:
2-[(2-{[(6S)-3-oxo-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-12-yl]amino}-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-4-yl)amino]acetic acid;
(6S)-12-[(4-{methyl[(3S)-oxolan-3-yl]amino}-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl)amino]-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-3-one;
(6S)-12-({4-[methyl(oxolan-3-yl)amino]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-3-one;
(6S)-12-[(4-{methyl[(1r,3r)-3-hydroxycyclobutyl]amino}-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl)amino]-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-3-one;
2-(dimethylamino)ethyl 7-({4-methoxy-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl}amino)-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(6S)-12-({4-[2-(morpholin-4-yl)ethoxy]-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-3-one;
(6S)-12-[(4-{methyl[(3R)-oxolan-3-yl]amino}-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl)amino]-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-3-one;
(6S)-12-({5-[4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl]-4-(prop-1-en-2-yl)pyridin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-3-one;
N-cyclopropyl-4-(4-methoxy-2-{[(6S)-3-oxo-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-12-yl]amino}pyrimidin-5-yl)-N-methylbenzamide;
3-methyl-1-(2-{[(6S)-3-oxo-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(13),9,11-trien-12-yl]amino}-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-4-yl)azetidine-3-carbonitrile;
12-({4-methoxy-5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl}amino)-4-[2-(morpholin-4-yl)ethyl]-8-oxa-2,4,10-triazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-3-one;
1-{4-[2-({2H,3H-[1,4]dioxino[2,3-b]pyridin-7-yl}amino)-4-{methyl[(1r,3r)-3-hydroxycyclobutyl]amino}pyrimidin-5-yl]phenyl}pyrrolidin-2-one;
2-(dimethylamino)ethyl 7-({5-[4-(5-methyl-1H-1,2,3-triazol-1-yl)phenyl]pyrimidin-2-yl}amino)-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
(6S)-12-({5-[4-(2-oxopyrrolidin-1-yl)phenyl]-4-(trifluoromethyl)pyrimidin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-3-one;
2-(dimethylamino)ethyl 7-({5-[4-(dimethylcarbamoyl)phenyl]-4-methoxypyrimidin-2-yl}amino)-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
1-{4-[2-({5-[4-(dimethylamino)piperidin-1-yl]pyridin-3-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one;
N-{5-[4-(dimethylamino)piperidin-1-yl]pyridin-3-yl}-4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-amine;
4-[2-({2H,3H-[1,4]dioxino[2,3-b]pyridin-7-yl}amino)-4-{methyl[(1s,3s)-3-hydroxycyclobutyl]amino}pyrimidin-5-yl]-N,N-dimethylbenzamide;
1-{4-[2-({1-[2-(dimethylamino)acetyl]-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one;
2-(dimethylamino)-1-[7-({5-[4-(5-methyl-1H-1,2,3-triazol-1-yl)phenyl]pyrimidin-2-yl}amino)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-1-yl]ethan-1-one;
(6S)-12-({5-[3-fluoro-4-(2-oxopyrrolidin-1-yl)phenyl]-4-[(3-hydroxyoxetan-3-yl)methyl]pyrimidin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-3-one;
2-(diethylamino)ethyl 7-[(5-{4-[(2R)-2-methyl-5-oxopyrrolidin-1-yl]phenyl}pyrimidin-2-yl)amino]-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
2-(diethylamino)ethyl 7-({5-[4-(2-oxopyrrolidin-1-yl)phenyl]pyrimidin-2-yl}amino)-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxylate;
N-[2-(diethylamino)ethyl]-7-[(4-methoxy-5-{4-[(2R)-2-methyl-5-oxopyrrolidin-1-yl]phenyl}pyrimidin-2-yl)amino]-N-methyl-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxamide;
N-[2-(diethylamino)ethyl]-N-methyl-7-[(5-{4-[(2R)-2-methyl-5-oxopyrrolidin-1-yl]phenyl}pyrimidin-2-yl)amino]-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxamide;
1-{4-[2-({1-[2-(diethylamino)ethyl]-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-7-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one;
(6S)-12-({5-[4-(dimethylphosphoryl)phenyl]pyridin-2-yl}amino)-8-oxa-2,10-diazatricyclo[7.4.0.02,6]trideca-1(9),10,12-trien-3-one;
2-{4-[5-({4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-yl}amino)pyridin-3-yl]piperazin-1-yl}ethan-1-ol;
N-[2-(diethylamino)ethyl]-7-[(5-{4-[(2R)-2-methyl-5-oxopyrrolidin-1-yl]phenyl}pyrimidin-2-yl)amino]-1H,2H,3H-pyrido[2,3-b][1,4]oxazine-1-carboxamide;
1-(4-{2-[(5-{[2-(4-ethylpiperazin-1-yl)-2-oxoethyl](methyl)amino}pyridin-3-yl)amino]-4-methoxypyrimidin-5-yl}phenyl)pyrrolidin-2-one;
N3-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-N5-{4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-yl}-N3-methylpyridine-3,5-diamine;
1-(4-{2-[(5-{[2-(4,4-difluoropiperidin-1-yl)ethyl](methyl)amino}pyridin-3-yl)amino]-4-methoxypyrimidin-5-yl}phenyl)pyrrolidin-2-one;
1-(4-{2-[(5-{[2-(3,3-difluoropyrrolidin-1-yl)ethyl](methyl)amino}pyridin-3-yl)amino]-4-methoxypyrimidin-5-yl}phenyl)pyrrolidin-2-one;
N-{5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl}-4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-amine;
1-{4-[2-({5-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one;
1-(4-{4-methoxy-2-[(5-{methyl[2-oxo-2-(piperazin-1-yl)ethyl]amino}pyridin-3-yl)amino]pyrimidin-5-yl}phenyl)pyrrolidin-2-one;
N-{5-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl}-4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-amine;
1-{4-[2-({5-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one;
1-(4-{4-methoxy-2-[(5-{methyl[3-oxo-3-(piperazin-1-yl)propyl]amino}pyridin-3-yl)amino]pyrimidin-5-yl}phenyl)pyrrolidin-2-one;
N-{5-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]pyridin-3-yl}-4-methoxy-5-[4-(4-methylpyridazin-3-yl)phenyl]pyrimidin-2-amine; and
1-{4-[2-({5-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]pyridin-3-yl}amino)-4-methoxypyrimidin-5-yl]phenyl}pyrrolidin-2-one.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 1)

A method of treating a disease or disorder associated with modulation of phosphatidylinositol-5-phosphate-4-kinase (PI5P4K) comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 11 (depends on 10)

The method of claim 10, wherein the disease or disorder associated with modulation of (PI5P4K) is a cancer or cell proliferative disorder, a metabolic disorder, a neurodegenerative disease, or an inflammatory disease.

### Claim 12 (depends on 1)

A method of inhibiting PI5P4K comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 13 (depends on 1)

A method of treating cancer or a cell proliferative disorder, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the cancer or cell proliferative disorder is leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (Hodgkin's disease, non-Hodgkin's disease), Waldenstrom's macroglobulinemia, heavy chain disease, or solid tumors such as sarcomas and carcinomas (e.g., fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcorna, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelioma sarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcorna, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms tumor, cervical cancer, uterine cancer, testicular cancer, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma).

### Claim 15 (depends on 1)

A method of treating a neurodegenerative disease comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neurodegenerative disease is brain trauma, spinal cord trauma, trauma to the peripheral nervous system, Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multisystem degeneration (Shy-Drager syndrome), motor neuron diseases including amyotrophic lateral sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease/spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, Gilles De La Tourette's disease, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy (Kennedy's disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffman disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, and prion diseases (including Creutzfeldt-Jakob, Gerstmann-Straussler-Scheinker disease, Kuru and fatal familial insomnia, age-related dementia, vascular dementia, diffuse white matter disease (Binswanger's disease), dementia of endocrine or metabolic origin, dementia of head trauma and diffuse brain damage, dementia pugilistica or frontal lobe dementia, neurodegenerative disorders resulting from cerebral ischemia or infarction including embolic occlusion and thrombotic occlusion as well as intracranial hemorrhage of any type, intracranial and intravertebral lesions, hereditary cerebral angiopathy, normeuropathic hereditary amyloid, Down's syndrome, macroglobulinemia, secondary familial Mediterranean fever, Muckle-Wells syndrome, multiple myeloma, pancreatic- and cardiac-related amyloidosis, chronic hemodialysis arthropathy, or Finnish and Iowa amyloidosis.

### Claim 17 (depends on 1)

A method of treating an inflammatory disease, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein the inflammatory disease is associated with a metabolic disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein the metabolic disorder is Type II diabetes, insulin resistance cardiovascular disease, arrhythmia, atherosclerosis, coronary artery disease, hypertriglyceridemia, dyslipidemia, retinopathy, nephropathy, neuropathy, or macular edema.

### Claim 20 (depends on 17)

The method of claim 17, wherein the inflammatory disease is associated with an inflammatory bowel disease.

### Claim 21 (depends on 20)

The method of claim 20, wherein the inflammatory bowel disease is ileitis, ulcerative colitis, Barrett's syndrome, or Crohn's disease.

### Claim 22 (depends on 10)

The method of claim 10, wherein administering is performed orally, parentally, subcutaneously, by injection, or by infusion.

### Claim 23 (depends on 10)

The method of claim 10, wherein the patient is selected for treatment based on gene amplification and/or elevated tumor expression of PI5P4K.

### Claim 24 (depends on 23)

The method of claim 23, wherein the gene amplified and/or expressed is PI5P4Kα gene, PI5P4Kβ gene, or PI5P4Kγ gene.

### Claim 25 (depends on 10)

The method of claim 10, wherein the patient is selected for the treatment based on tumor expression of p53 mutations.

### Claim 26 (depends on 10)

The method of claim 10, wherein administration of the compound induces a change in the cell cycle or cell viability.

### Claim 27 (depends on 1)

A method of inducing cell cycle arrest, apoptosis in tumor cells, and/or enhanced tumor specific T-cell immunity, comprising contacting the cells with an effective amount of a compound of claim 1.

### Claim at position 28

-29. (canceled)
